Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab
American Journal of Nephrology · 2024
DOI: 10.1159/000541972 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Yuxin Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Rituximab, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Rituximab has proven effective and safe in pediatric and adult minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) patients with frequently relapsing nephrotic syndrome. However, its efficacy diminishes in several patients who experience nephrotic syndrome relapsing in short durations or failing to achieve remission. We aimed to explore the efficacy and safety of obinutuzumab, a novel anti-CD20 antibody, in these patients.
Methods
A retrospective case series study at our center included 11 adult MCD or FSGS patients who presented with nephrotic syndrome characterized by short-duration relapses or lack of remission after multitarget therapy, including rituximab. Primary outcomes included the first relapse-free time, relapse rate during follow-up, and the use of immunosuppressants after obinutuzumab. All adverse events were recorded.
Results
Eleven adult patients (median age 26.0 years, 81.9% males) received an average obinutuzumab dose of 2.0 (1.0, 2.0) g during a median follow-up period of 17.0 (12.0, 22.0) months. The first relapse-free time was 12.1 (10.8, 18.9) months. Two patients with FSGS experienced relapses, while the remaining maintained remission by the end of follow-up. Six patients (54.5%) achieved cessation of corticosteroids and immunosuppressants within 3 months after obinutuzumab. Adverse events were mostly mild.
Conclusion
Obinutuzumab may be an efficient and safe option for inducing remission in adult MCD and FSGS patients who presented with nephrotic syndrome relapsing in short durations or failed to achieve remission after multitarget therapy, including rituximab. It was effective in maintaining remission in MCD patients, while its efficacy in maintaining remission in FSGS patients remained uncertain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Institute of Nephrology, Zhejiang University, Hangzhou, China.
- National Key Clinical Department of Kidney Diseases, Hangzhou, China.
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China.
Zitieren
APA
Lin, Y., Pan, Y., Han, Q., Xu, J., Wang, J., Lei, X., Chen, L., Wang, Y., Ren, P., Lan, L., Chen, J., & Han, F. (2024). Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab. American Journal of Nephrology. https://doi.org/10.1159/000541972
Vancouver
Lin Y, Pan Y, Han Q, Xu J, Wang J, Lei X, et al. Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab. American Journal of Nephrology. 2024. doi:10.1159/000541972
BibTeX
@article{Lin2024,
author = {Lin, Yuxin and Pan, Yixuan and Han, Quan and Xu, Jianhang and Wang, Junni and Lei, Xin and Chen, Liangliang and Wang, Yaomin and Ren, Pingping and Lan, Lan and Chen, Jianghua and Han, Fei},
title = {Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab},
journal = {American Journal of Nephrology},
year = {2024},
doi = {10.1159/000541972}
}
EUVIMED